Latest Guides

Business News

Pasadena-based Artificial Intelligence Company Develops Software To Find Patients for Clinical Trials in Minutes

Published on Saturday, October 30, 2021 | 5:39 am
 
[Photo by SofikoS/Shutterstock]

Pasadena-based Deep 6 AI, which supplies clinical trial acceleration software to help defeat disease and get life-saving therapies to market faster, has launched Deep 6 for Life Sciences, a novel suite of AI software solutions for life science sponsors and contact research organizations.

Using cutting-edge Artificial Intelligence to mine the entire patient record, Deep 6 for Life Sciences brings a new level of data-driven precision and insight to sponsors’ interventional and observational studies, saving them months and significantly ‘de-risking’ their research efforts, a company statement said.

Jason Attanucci, Vice President of Life Sciences at Deep 6 AI, said the software was developed for clinical researchers and site coordinators at life science companies, so they can prove the efficacy of their products and get them to market faster.

“The biggest bottleneck in clinical trials is finding and enrolling patients,” Attanucci said. “Our software allows life sciences companies to look into the Deep 6 ecosystem of over 30 million patients to find exact matches for their trials. It allows life science companies to search across multiple sites in real-time so they know before they start a trial whether they have enough patients and where those patients are located.”

The software also allows life science companies to publish their studies to the ecosystem so that all doctors, not just researchers, can be aware of which clinical trials are available for their patients, Attanucci added.

“Patients are over 20 times more likely to join a clinical trial if it is recommended to them by a doctor that they trust,” he said.

Deep 6 AI illustrated AI’s benefits in a recent Crohn’s Disease study which showed traditional methods of verification identifying 5,024 eligible patients. This number dropped to 30 after months of manual record verification, the study showed, but Deep 6 AI software found and validated 36 eligible patients in less than 45 minutes.

The company said this is important because new drug development is inherently costly, slow, and fraught with risk. According to data from the National Center for Biotechnology Information (NCBI), investments averaging $1 to $1.8 billion and 12 years are needed to bring a new treatment to market, the statement said.

Further NCBI analysis showed that 55 percent of clinical trials were terminated due to low accrual rates. Globally, more than 80 percent of trials fail to enroll on time, according to the statement.

“Well over a decade into precision medicine and clinical data digitization, most studies still resort to a ‘spray and pray’ approach, contacting as many patients as possible and then spending months manually picking the few who actually match the study criteria,” Wout Brusselaers, Deep 6 AI CEO, said. “Our technology upends this approach, by starting from precision-matching eligible patients to exact research criteria upfront, in mere minutes instead of months.”

Deep 6 AI said sponsors and CROs can learn more about Deep 6 for Life Sciences at the CNS Summit, November 7 to 10 in Boston, Massachusetts.

Founded in 2016 in Pasadena, Deep 6 AI is a Techstars and StartX alum. For more information, visit www.deep6.ai.

Get our daily Pasadena newspaper in your email box. Free.

Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m.

Make a comment

Your email address will not be published. Required fields are marked *

 

 

 

buy ivermectin online
buy modafinil online
buy clomid online
buy ivermectin online